Smoking-Induced Polycythemia

Mechanism and Diagnosis

Smoker's polycythemia is a real and recognized form of secondary polycythemia that is caused by chronic exposure to carbon monoxide from cigarette smoke, leading to increased red blood cell production to maintain adequate tissue oxygenation 1, 2
Carbon monoxide in cigarette smoke binds to hemoglobin with an affinity 200-250 times greater than oxygen, forming carboxyhemoglobin, which reduces oxygen-carrying capacity 3
This relative hypoxic state triggers compensatory erythropoiesis, resulting in increased hematocrit, hemoglobin concentration, and red blood cell count 2

Smoking-induced polycythemia increases blood viscosity, which raises the risk of thrombotic events, with smoking associated with a 1.8-fold increased risk of stroke 4, 5
The primary treatment for smoker's polycythemia is smoking cessation, which can lead to resolution of polycythemia and reduction in cardiovascular risk 2
Risk reduction begins within 1 year of smoking cessation, with return to baseline risk after 5 years 4, 5

After smoking cessation, hematological parameters should be monitored to confirm resolution of polycythemia, and patients should be counseled about the increased cardiovascular risk associated with both smoking and polycythemia 2, 4, 5

The American College of Cardiology and other guideline societies recommend smoking cessation as the primary treatment for smoker's polycythemia, with a strong evidence base supporting its effectiveness 2
The strength of evidence for the causal relationship between smoking and increased hematocrit, hemoglobin, and mean corpuscular volume is high, based on studies such as those published in the Mayo Clinic Proceedings 2

Smokers typically maintain carboxyhemoglobin (COHb) levels of 3-5%, with approximately 2.5% increase per pack of cigarettes smoked daily, according to the American Thoracic Society 6, 7, 8
Heavy smokers can reach COHb levels exceeding 10%, particularly those with underlying lung pathology, as reported by the American Thoracic Society 8

Standard pulse oximeters cannot differentiate carboxyhemoglobin from oxyhemoglobin, potentially masking the severity of impaired oxygen delivery, as noted by the American Thoracic Society 7
The classic "cherry red" skin appearance is rare and requires lethal COHb levels; its absence does not exclude significant CO exposure, according to the American Thoracic Society 6, 7

Smoking induces eryptosis, a premature red blood cell death with phosphatidylserine externalization, which correlates with plasma CRP levels and promotes vascular inflammation, as reported by Cell Death and Disease 9
The level of eryptotic cells positively associates with the number of cigarettes smoked daily, indicating a dose-dependent relationship between smoking and eryptosis, as found in a study published in Cell Death and Disease 9

Smoking‑induced polycythemia raises blood viscosity and increases the risk of ischemic stroke by approximately 1.8‑fold. 10
The extent of eryptosis (premature red‑cell death) shows a dose‑response relationship with daily cigarette consumption; higher cigarette counts correlate with greater eryptotic cell levels. 10

At the 2–4 week visit, clinicians should assess current smoking behavior by directly asking the patient whether the number of cigarettes smoked has changed since the initial encounter. 11
Evaluation for obstructive sleep apnea should be incorporated, including questions about witnessed apneas, loud snoring, morning headaches, and daytime somnolence. 11

The European Society of Cardiology recommends that smoking cessation reduces cardiovascular risk within 1 year, with risk returning to baseline after roughly 5 years of abstinence. 12
First‑line pharmacologic aids—nicotine‑replacement therapy, bupropion, or varenicline—are effective and have not been linked to an increased incidence of major adverse cardiovascular events. 12
Combining behavioral counseling with pharmacologic therapy yields the highest cessation success rates. 12
E‑cigarettes should not be recommended as a cessation tool because they are not risk‑free and have been associated with the development of polycythemia. 12

Therapies that alter red‑cell turnover, such as erythropoietin treatment, can interfere with the accuracy of hemoglobin A1c measurements, potentially producing misleading glycemic assessments. 13
When A1c results are discordant with clinical glucose measurements in smokers with polycythemia, clinicians should use alternative metrics such as fasting plasma glucose or continuous glucose monitoring. 14